Core Insights - BrainsWay Ltd. has introduced new clinical data demonstrating a significantly faster, noninvasive treatment for depression, reducing the acute treatment phase by 70% without compromising efficacy [1][2][3] Group 1: Clinical Efficacy - The SWIFT™ accelerated Deep TMS™ protocol achieved an 87.8% response rate and a 78.0% remission rate, comparable to traditional protocols while requiring fewer treatment days [11] - Median time to remission was reduced to 21 days with SWIFT compared to 28 days under the standard protocol [11] - Approximately 60% of patients returned to normal-range functioning after treatment, and 70% no longer suffered from severe quality of life impairment [9][12] Group 2: Patient Impact - Patients reported earlier symptom improvement and substantial enhancements in quality of life, with scores improving by approximately 32 percentage points from baseline by week six [12] - The proportion of patients experiencing severe functional impairment decreased from 85-100% at baseline to 15-17% by the end of treatment [12] - Patients are reconnecting with work, relationships, and routines, highlighting the human impact of the treatment [6] Group 3: Market Implications - The SWIFT approach could transform interventional psychiatry by improving patient retention and expanding clinical options, especially as demand for non-drug therapies rises [3][4] - The economic burden of Major Depressive Disorder (MDD) in the U.S. is estimated at $333 billion annually, with time constraints being a significant barrier to treatment access [4] - Payers are reducing administrative barriers, such as eliminating prior authorization requirements for Deep TMS, which may enhance accessibility [6]

Core Insights - BrainsWay Ltd. has introduced new clinical data demonstrating a faster, noninvasive treatment for depression, enhancing its neuromodulation platform aimed at improving brain health [1][2] Group 1: Clinical Efficacy - The SWIFT™ accelerated Deep TMS™ protocol achieved an 87.8% response rate and a 78.0% remission rate for Major Depressive Disorder, comparable to traditional methods [10] - The median time to remission was reduced to 21 days with SWIFT compared to 28 days under the standard protocol [10][8] - Approximately 70% of participants reported no longer suffering from severe quality of life impairment, and around 60% returned to normal functioning after treatment [9] Group 2: Patient Experience - Patients reported earlier symptom improvement and significant enhancements in quality of life, with scores improving by approximately 32 percentage points from baseline by week six [11] - The proportion of patients experiencing severe functional impairment decreased from 85-100% at baseline to 15-17% by the end of treatment [11] Group 3: Accessibility and Impact - The SWIFT approach reduces the number of clinic visits in the acute phase by about 70%, addressing logistical barriers that hinder access to treatment [3][4] - The innovation is expected to improve patient retention and expand clinical options, particularly as demand for non-drug therapies rises [3][4] - BrainsWay's CEO emphasized the importance of addressing accessibility and scalability in mental health innovation, marking a new era for the company [7]